Genetic Counseling & Ethics in Neurogenetics

Genetic counseling is often misread as the act of explaining a test result. Its formal definition (NSGC, Resta et al. 2006) — helping people understand and adapt to the medical, psychological, and familial implications of genetic disease — deliberately puts adaptation alongside understanding. The information is necessary but not sufficient; the work is helping a person integrate that information into a life already in progress.

Why non-directiveness, and what it is not

The field's commitment to non-directiveness is a historical reaction against the eugenics era, when 'genetic advice' meant steering reproduction toward state-defined goals. Modern counseling instead protects autonomy: the counselor supplies balanced information and helps clarify the patient's own values, but does not tell them what to choose. Non-directiveness is not withholding an opinion when asked a factual question, nor pretending all outcomes are equivalent. It means the decision — to test, to continue a pregnancy, to inform a relative — belongs to the patient, because they alone bear its consequences.

Pre-test counseling sets up everything downstream

• A three-generation pedigree is diagnostic reasoning in visual form: it reveals inheritance pattern, identifies the most-informative person to test first, flags consanguinity (raising prior probability of recessive disease), and surfaces at-risk relatives who may need cascade testing later. The 2022 focused revision of the NSGC standardized nomenclature (Bennett et al. 2022) draws each person's symbol by gender identity (square, circle, or diamond for a non-binary person or unknown gender) and writes sex assigned at birth (AFAB, AMAB, UAAB) beneath it where clinically relevant, as it often is for X-linked conditions.
• Test selection is a deliberate trade-off, not a default to the broadest test. A targeted panel or repeat-expansion assay gives a cleaner yes/no with fewer incidental findings; exome/genome cast a wider net but generate more VUS and secondary findings — each of which becomes its own counseling burden.
• The single most important pre-test task is anticipatory guidance: walking through the full menu of outcomes before the sample is drawn — a definitive diagnosis, a VUS that resolves nothing, a secondary finding in an ACMG SF gene, a truly negative result that still leaves residual risk, and unexpected findings such as misattributed parentage. A family that has rehearsed these possibilities makes a more autonomous choice and is far less destabilized by an ambiguous report.

Informed consent is the documented product of that conversation: purpose, the result types above, test limitations, implications for blood relatives, insurance considerations, and — explicitly — the right to decline any or all of it.

Post-test counseling is where adaptation actually happens: disclosure in a supportive setting, correlation of the variant to the phenotype, psychosocial support, specialist coordination, and — for the common uninformative result — an honest account of residual risk plus a concrete plan for re-analysis, since today's VUS may be reclassified as the evidence base grows.

Predictive testing is fundamentally different from diagnostic testing: the person in front of you is well. There is no symptom to relieve, no treatment to start. The result changes only what they know about their future — and knowledge, once given, cannot be returned. That asymmetry is why predictive testing has its own protocol rather than being treated as just another lab order.

Why Huntington disease became the paradigm

HD is the worst-case template: autosomal dominant, fully penetrant at 40 or more CAG repeats over a normal lifespan, adult onset, and still without an approved disease-modifying treatment (October 2026). The result is a number, and its meaning depends on where it falls: 26 or fewer is normal; 27–35 is intermediate (the person is not expected to develop HD, but a paternally transmitted allele can expand into the disease range); 36–39 is reduced penetrance (some carriers never develop symptoms in a normal lifespan); 40 or more is full penetrance, with longer repeats predicting earlier onset in aggregate but not precisely for an individual.

The protocol slows an irreversible decision

The European recommendations (MacLeod et al. 2013) and the Huntington's Disease Society of America protocol (2016) share a structure: pre-test counseling about inheritance, the meaning of each result and insurance; a mental health assessment; informed consent; and results given in person, with a companion if the person wants one, never by telephone or letter. The European recommendations set a reflection interval of at least one month between pre-test information and the decision to test, and recommend (but do not require) a psychological appraisal; the HDSA protocol includes a mental health assessment. The person may decide at any point not to hear the result. HDSA's 2016 revision reduced the protocol from four visits to two (a pre-test visit combining counseling, mental health assessment, neurological examination, consent and blood draw, then a results visit) and made the neurological examination and the support person optional (Goldman 2020). Minors are not tested for HD except in rare circumstances. Goldman et al. 2026 argue that the protocol, unchanged since 2016, needs updating for telemedicine, patient-portal access to results, and HD status revealed incidentally by genomic sequencing. Uptake has always been low: only 4–24% of people at risk chose testing once it became available.

The right not to know is a real and protected interest

Autonomy includes the freedom to not learn one's genetic future, and this right can collide with a relative's wish to test. The classic conflict: a grandchild's positive HD result almost certainly shows that an intervening parent — who chose not to know — also carries the expansion. The grandchild's request is legitimate and does not depend on the parent's consent, so counseling raises the conflict before testing, explores whether the family can talk, and plans for how a positive result would be handled. Prenatal exclusion testing applies linkage to the same problem one generation down: it shows whether a fetus inherited the affected grandparent's chromosome 4 (leaving the fetus at the parent's 50% risk) or the other grandparent's (risk close to none), without testing the at-risk parent.

Beyond HD

The HD structure is used for other adult-onset predictive tests, where the answer is usually less certain. C9orf72 expansions have incomplete, age-dependent penetrance and can cause ALS, FTD or both within one family. For SOD1, tofersen received FDA accelerated approval in 2023 for SOD1-ALS, and the ATLAS trial is testing it in presymptomatic carriers whose neurofilament light chain begins to rise — so a positive result can now lead to monitoring and trial eligibility. For PRNP, penetrance depends on the variant: near complete for common variants such as E200K, D178N and P102L, low for some others (Minikel et al. 2016); no therapy is approved, and a PrP-lowering antisense drug (ION717) is in a phase 1/2 trial.

The insurance gap patients rarely anticipate

In the US, GINA (2008) bars genetic discrimination by health insurers and by employers with 15 or more employees — but its protection stops there. It does not cover life, disability or long-term-care insurance, smaller employers, or the US military, and it protects genetic information rather than manifest disease. Some states go further: Florida's 2020 law bars life and long-term-care insurers from using genetic test results in the absence of a related diagnosis. Counseling people to arrange these policies before testing is concrete advice that protects them where federal law does not.

Both results can harm

In a worldwide survey of 4,527 people after HD predictive testing, 44 (0.97%) had a catastrophic event — suicide, suicide attempt or psychiatric hospitalization (Almqvist et al. 1999). All five suicides were in people already showing signs of HD; of 13 events in asymptomatic people in the first year, 11 followed an increased-risk result; recent psychiatric history and unemployment raised the risk. Distress is not confined to bad news: a negative result can bring survivor guilt and the loss of an identity organized for years around being at risk, which is why post-result support is offered regardless of the answer.

Pediatric testing turns on a question no other patient group raises: the person being tested cannot consent, yet the result follows them for life. The guiding rule is therefore not 'can we test?' but 'does this child benefit from knowing now?' — with the child's future autonomy treated as a real asset to be protected, not a formality to be waived.

The deciding question: childhood medical actionability

Testing a child is appropriate when the result changes management during childhood. The benefit is concrete and the autonomy cost is justified by it:

• TSC: molecular confirmation triggers a defined surveillance schedule (brain MRI, renal ultrasound, echocardiography, ophthalmology) that catches SEGAs, renal angiomyolipomas, and cardiac rhabdomyomas before they cause harm. Knowing the diagnosis early demonstrably improves outcomes.
• SMA: this is the strongest case, because the therapeutic window is biological, not bureaucratic. Motor neurons lost before treatment do not return, so nusinersen, onasemnogene abeparvovec, and risdiplam are dramatically more effective presymptomatically — every day of delay can cost irreplaceable neurons. See the Genetic Neuromuscular Disorders module.

*Why we deliberately don't test for adult-onset conditions*

For a condition like HD with no childhood intervention, the AAP and ACMG (2013) and the ASHG (Botkin et al. 2015) recommend deferring until the individual can decide for themselves; the ASHG also encourages adolescents to defer, allowing exceptions to relieve substantial psychosocial distress or for specific life-planning decisions. The reasoning is symmetrical with the predictive-testing protocol: testing the child captures no medical benefit while permanently foreclosing their right to decide whether they ever want to know. Parental authority to consent for medical care does not extend to surrendering a competency that belongs to the future adult.

Newborn screening makes this a population-scale problem

NBS shifts these decisions from individual families to public-health policy. SMA was added to the US RUSP in 2018 and, by early 2024, was screened in all 50 states — a genuine success, because it operationalizes presymptomatic SMA treatment at scale. But each candidate condition reopens the actionability debate: should the panel include disorders with variable expressivity (where a positive screen may never become disease) or uncertain treatment efficacy (where early knowledge brings anxiety without clear benefit)? The threshold for inclusion is an ethical judgment, not just a technical one.

Genome-wide newborn screening pushes the tension to its limit

Pilots show both sides. GUARDIAN in New York screened its first 4,000 newborns for 156 actionable conditions: 3.7% screened positive, most often for G6PD deficiency, and 110 confirmed conditions had not been flagged by standard screening (Ziegler et al. 2025). BabySeq found unanticipated childhood-onset disease risk in 15 of 159 newborns (9.4%) and actionable adult-onset risk in 3 of 85 whose parents agreed to receive it (Ceyhan-Birsoy et al. 2019), and England's Generation Study aims to sequence 100,000 newborns for more than 200 conditions. Genome-wide screening can flag many treatable conditions from a single sample — but at the cost of generating VUS in healthy infants, occasionally surfacing adult-onset risks the child never consented to learn, and creating the 'patient-in-waiting': a well child medicalized by a probabilistic result, subjected to surveillance and parental anxiety for a disease that may never arrive.

Once you sequence an exome or genome, you have, in effect, read genes you never intended to look at. Some of those genes carry pathogenic variants that — independent of why the test was ordered — predict a serious but preventable disease. The ACMG's response is the concept of opportunistic screening: since the data already exist, deliberately mine a curated list of genes and report back the ones where acting now can avert harm. A variant found this way is a secondary finding (SF) — sought on purpose, but unrelated to the indication.

The list is defined by actionability, not by severity or interest

• Current version: ACMG SF v3.3 (2025), 84 genes (Lee et al. 2025): 41 cardiovascular, 28 cancer predisposition, 7 inborn errors of metabolism and 8 other genes. The list is revised roughly annually and is a minimum, not a ceiling.
• The inclusion bar is narrow and specific: a gene earns a place only when an established intervention can prevent or substantially reduce morbidity and mortality. That is why the list is dominated by hereditary cancer (BRCA1/BRCA2, the Lynch mismatch-repair genes, TP53), inherited cardiovascular disease (cardiomyopathies, long-QT and other arrhythmias, aortopathies), malignant hyperthermia (RYR1, CACNA1S), and familial hypercholesterolemia. A devastating but unactionable finding does not qualify — there is no benefit to offset the burden of knowing.
• Only P/LP variants in listed genes count. A VUS is never reported as an SF (acting on uncertain evidence would cause net harm), and a pathogenic variant in a gene off the list is not sought.

Consent is a duty to offer, not a default to report

• ACMG frames SF as something the patient must be offered and may decline (opt out) at consent (ACMG 2015) — the patient's right not to know applies here just as it does in predictive testing.
• Laboratories operationalize this differently; many require an explicit opt-in rather than honoring a true opt-out default, so SF are not automatically returned everywhere.
• The practical consequence for the ordering clinician is non-negotiable: offer the choice and document the decision before the sample is sent. Discovering after the fact that a patient was never asked is both an ethical and a medico-legal failure.

The pediatric tension — and why ACMG accepts it

• The SF list is applied regardless of age. An adult-onset finding such as a pathogenic BRCA variant can therefore be returned from a child's exome ordered for an unrelated reason like epilepsy.
• This openly contradicts the rule, two sections up, that we defer predictive testing for adult-onset conditions in minors. ACMG accepts the contradiction on two grounds: the finding is incidental (ascertained while pursuing the child's own care, not by targeted predictive testing of the child), and it carries direct benefit to the family — a BRCA variant in the child usually traces to an at-risk parent who can act today. The justification is genuinely contested; the v3.3 statement itself says the best interest of children should still be prioritized, and the ASHG would offer such findings to parents only when they have clear utility for the child or family, letting parents decline in advance except for urgent, actionable findings.

When an SF returns the response is procedural: confirm the variant on an independent sample, refer to the relevant specialty (oncology, cardiology, genetics), offer cascade testing to at-risk relatives, and start guideline-based surveillance. The point of the whole enterprise is realized only at this step — a finding nobody was looking for becomes a prevented cancer or a recognized arrhythmia.

The complete ACMG SF v3.3 list (84 genes)

Only pathogenic or likely-pathogenic variants in these genes are reported as secondary findings. The tables below group the genes by organ system for teaching; ACMG's own table groups them as cancer predisposition (28), cardiovascular (41), inborn errors of metabolism (7) and other (8). The three genes added in v3.3 are flagged below — ABCD1 (X-linked adrenoleukodystrophy) and CYP27A1 (cerebrotendinous xanthomatosis) are treatable neurometabolic disorders of particular relevance to neurology, and PLN is a cardiomyopathy gene.

Hereditary cancer

Cardiovascular (cardiomyopathy, arrhythmia, aortopathy, hypercholesterolemia, malignant hyperthermia)

Connective tissue & vascular

Metabolic

Paraganglioma-pheochromocytoma

Ophthalmologic

The reproductive options below are not a menu to be ranked from best to worst — they map onto profoundly different values: how a couple weighs the risk of an affected child, their stance on pregnancy termination, their tolerance for the burden and cost of IVF, and their views on disability itself. The counselor's job is to make the trade-offs visible, then step back. Timing is the one thing that is objectively better earlier: every option except prenatal diagnosis depends on planning before conception.

Carrier screening — knowing the risk before there is a pregnancy

ACMG's 2021 practice resource (Gregg et al. 2021) defines tiers by carrier frequency and recommends Tier 3 — conditions with a carrier frequency of 1 in 200 or higher, 97 autosomal recessive and 16 X-linked genes — for everyone pregnant or planning a pregnancy, regardless of ancestry; Tier 4 (no frequency floor) is reserved for consanguinity (second cousins or closer) or a suggestive history. The shift away from ethnicity-based panels is deliberate: self-reported ancestry is a poor proxy for which variants someone carries, and admixture makes targeted panels miss carriers. ACOG (Committee Opinions 690/691) still accepts ethnic-specific, pan-ethnic, and expanded approaches as reasonable. Panels capture SMA, Tay-Sachs, Canavan, the Fragile X premutation, and more. The decisive value of screening is that a couple found to be at risk still has every option open — they learn before there is a pregnancy to make decisions about.

Prenatal diagnosis — definitive, but inside an established pregnancy

• CVS (10–13 weeks) or amniocentesis (from 15 weeks) give a definitive fetal diagnosis at a small procedure-related miscarriage risk. They are the right tool when a couple accepts pregnancy and wants certainty, but they place any decision about an affected fetus in the emotionally and ethically harder context of continuing or ending a wanted pregnancy.

PGT-M — moving the decision before pregnancy begins

Preimplantation genetic testing for monogenic disorders pairs IVF with biopsy of blastocyst-stage embryos so that only unaffected embryos are transferred. Its appeal is precisely that it relocates selection to before implantation, sidestepping prenatal diagnosis and possible termination — which is why it is often the answer for couples who decline the latter. The trade-offs are real: it requires IVF (cost, hormonal stimulation, no guarantee of a viable embryo) and an assay developed in advance for the family's specific variant. It works for essentially any monogenic condition with a known variant — HD, SMA, TSC, SCN1A.

NIPS — a screen, not a diagnosis, and the distinction is clinically dangerous to blur

Cell-free DNA screening is excellent for common aneuploidies (trisomy 21/18/13). For rare microdeletions like 22q11.2 it is treacherous: because the condition is rare in the population, even a very specific test yields a low positive predictive value, so many positive results are false positives: in the prospective SMART study, the positive predictive value for 22q11.2 deletion was 23.7% with the original algorithm and 52.6% with an updated one (Dar et al. 2022). A positive NIPS for a rare condition is a flag to confirm, never a result to act on — confirmatory CVS or amniocentesis is mandatory before any irreversible decision.

Reproductive autonomy frames all of it. Disability-rights perspectives rightly challenge the unexamined assumption that a genetic condition is something to be prevented, and a non-directive counselor presents that view honestly rather than presuming the couple shares the clinic's defaults. Donor gametes, embryo donation, and adoption round out the options for those who decline to pass on a known variant. For pathogenic mitochondrial DNA variants, the UK's licensed pronuclear-transfer pathway reported 8 live births in 2025, all healthy at birth with low or undetectable maternal-variant levels in blood (McFarland et al. 2025).

Genomics generates ethical problems faster than guidelines can settle them, because the underlying data are durable, shared, and constantly reinterpreted. A genetic result is not a snapshot that expires — it is a standing claim about a person and their relatives whose meaning changes as knowledge accumulates. Most of the dilemmas below stem from that single property.

Duty to recontact — the result that changes after you've moved on

When a VUS is later reclassified to P/LP (or downgraded to benign), the original report was accurate when issued but may now be wrong in a clinically important way. Beneficence argues for recontacting the patient; logistics argue against a blanket mandate — clinics close, patients move, and the volume of reclassifications is large. No society imposes a universal duty. The ACMG's points to consider (David et al. 2019) ask laboratories to issue amended reports to the ordering clinician, and share responsibility among laboratory, clinician and patient. The defensible middle ground is systematic re-analysis workflows plus honesty at consent that reclassification can happen and that the patient shares responsibility for staying reachable.

Duty to warn relatives

A pathogenic variant is a risk estimate for every blood relative. The usual route is the patient, helped by a family letter. The ASHG's 1998 statement (PMC1376910) would permit disclosure over a patient's objection only when attempts to encourage disclosure have failed, harm is highly likely, serious and foreseeable, the relative is identifiable, and the disease is preventable or treatable. US courts have differed: Pate v. Threlkel (Florida, 1995; medullary thyroid carcinoma) held that the duty is met by warning the patient, while Safer v. Estate of Pack (New Jersey appellate court, 1996; familial polyposis) suggested that warning the patient may not always suffice.

Data sharing — a tension between privacy and collective benefit

Variant classification is only as good as the aggregated evidence behind it, and databases like ClinVar and DECIPHER exist because labs contribute. Sharing de-identified data is supported by beneficence: every contributed variant helps resolve someone else's VUS. The cost is privacy and the limits of de-identification, which is why consent should address data-sharing explicitly rather than burying it.

Direct-to-consumer testing — the false-reassurance trap

DTC products (e.g., 23andMe reporting APOE ε4 and, under a 2018 FDA authorization, three BRCA1/BRCA2 founder variants most common in Ashkenazi Jewish ancestry) test a handful of variants, not whole genes. A negative DTC BRCA result in someone with a strong family history is dangerously misleading — it excludes only the specific founder variants screened, not the hundreds of other pathogenic variants. DTC results are leads to confirm with clinical-grade testing, never a basis for medical decisions. Privacy is the other risk: when 23andMe went bankrupt in 2025, its customers' genetic data were sold, with court approval, to a nonprofit research institute led by the company's co-founder; customers could delete their data, and nearly 2 million of 15 million had done so beforehand.

Equity — inequity built into the reference data

Access to genetic counselors is constrained, but the deeper problem is structural: populations underrepresented in gnomAD and ClinVar receive higher VUS rates (shown, for example, in a pediatric epilepsy cohort; Martin et al. 2024), because a variant cannot be confidently called benign or pathogenic without enough same-ancestry data. The result is that the people already least served by genetics get the least interpretable answers — a self-reinforcing inequity that telegenetics widens access to but does not fix; only diversifying the databases does.

Emerging frontiers

• Polygenic embryo selection (PGT-P) is sold commercially, but the ACMG judged in 2024 that it is not appropriate for clinical use (Grebe et al. 2024).
• Polygenic risk scores for neuropsychiatric conditions have limited clinical utility and perform poorly across ancestries (they are trained largely on European-ancestry cohorts), raising the twin risks of misleading low-confidence predictions and genetic determinism — treating a probabilistic score as destiny.
• Somatic gene editing is now clinical reality (CRISPR-based therapy for sickle cell disease), correcting cells in one consenting patient. Germline editing, which would alter all descendants who never consented, remains prohibited in most jurisdictions — the bright line being heritability and the inability of future generations to agree.